Iantrek announces first commercial cases of C.Rex micro-interventional system

News
Article

C.Rex is the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.

Technological graphic of eye Image credit: AdobeStock/ImageFlow

Image credit: AdobeStock/ImageFlow

Medical technology company Iantrek has announced the first commercial cases of its micro-interventional system for canal outflow enhancement designed for glaucoma surgery.1 The cases are part of the company’s pre-launch activities that features the C.Rex technology, used as an ophthalmic surgical system for canal outflow gonio-intervention, according to a news release.

“All conventional approaches have focused on the trabecular meshwork and the inner canal wall,” said Carol Toris, PhD, professor at the University of Nebraska Medical Center, in the release. “We have shown empirically and presented our study at ARVO that dual canal intervention can lead to incremental outflow enhancement over single inner wall goniotomy. Iantrek’s approach is uniquely original as it is able to address outflow resistance in the entire canal.”

C.Rex is a super-elastic nitinol filament technology and remains the only FDA-registered MIGS technology for excisional circumferential trabeculorhexis and dual wall canal intervention. The nitinol filament technology allows for flexible micro-instrumentation with memory-shaped super-elasticity to deliver 360-degrees of excisional, single, or dual wall canalotomy. C.Rex is also the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.1

“There are a lot of trabecular technologies, but this is an interventional breakthrough in non-implantable trabecular outflow surgery,” said Arkadidy Yadgarov, MD, of OMNI Eye Services in Atlanta, GA, and the first surgeon in the country to utilize the advanced technology, in the release. “It is one of the most surgically intuitive MIGS technologies, and the only goniotomy system to enable surgical intervention on the entire canal, not just segmentally. The C.Rex offers circumferential excisional goniotomy which is guided, continuous, comprehensive and can reduce resistant in the outer wall.”

Reference:
  1. Iantrek announces first commercial cases of its C.Rex micro-interventional system for trabecular outflow enhancement. News release. Iantrek. January 13, 2025. Accessed February 3, 2025. https://iantrekmed.com/iantrek-announces-first-commercial-cases-of-its-c-rex-micro-interventional-system-for-trabecular-outflow-enhancement/
Recent Videos
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Optometrists reflect on their residency experiences and provide advice to current residents.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
© 2025 MJH Life Sciences

All rights reserved.